Metastasis promoter S100A4 is a potential molecular therapeutic target

Cancer Genomics and Proteomics

Volumn 3, Issue 3-4, 2006, Pages 203-216

  Sherbet, G V ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b INSTITUTE FOR MOLECULAR MEDICINE   (United States)

Author keywords

Angiogenesis; Cancer invasion; Cell cycle regulation; Cytoskeletal dynamics; Growth factor signalling; Lymphangiogenesis; Metastasis; Review; S100A4; Therapeutic target; VEGF signalling

Indexed keywords

ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; CALVASCULIN; CONNECTIVE TISSUE GROWTH FACTOR; CONNECTIVE TISSUE GROWTH FACTOR CCN3; ERLOTINIB; GEFITINIB; GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HER2; PERTUZUMAB; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; TRANSCRIPTION FACTOR ETS; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANGIOGENESIS; CALCIUM SIGNALING; CANCER GROWTH; CANCER INVASION; CANCER RESEARCH; CARCINOGENESIS; CELL ADHESION; CELL CYCLE REGULATION; CELL MOTILITY; CLINICAL TRIAL; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; LYMPHANGIOGENESIS; METASTASIS; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 33746604070     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Sherbet GV: The Molecular and Cellular Pathology of Cancer Progression and Prognosis. Research Signpost, Trivandrum, 2006.
2. Sherbet GV and Lakshmi MS: The Genetics of Cancer. Academic Press, London, 1997.
3. Sherbet GV: Calcium Signalling in Cancer. CRC Press, Boca Raton, FL, 2001.
4. Grey SR, Dlay SS and Sherbet GV: Prediction of nodal spread of breast cancer by artificial neural network-based analyses of S100A4, nm23 and steroid receptor expression. Clin Exptl Metastasis 20: 507-514, 2003.
5. Sherbet GV and Lakshmi MS: The modus operandi of S100A4 signalling in cancer growth, progression and prognosis. In: Molecular and Cellular Pathology of Cancer Progression and Prognosis. Sherbet GV (ed.). Research Signpost, Trivandrum, pp. 359-377, 2006.
6. Sherbet GV: Genetic Recombination in Cancer. Academic/Elsevier, London, New York, 2003.
7. Parker C, Lakshmi MS, Piura B and Sherbet GV: Metastasis associated mts1 gene expression correlates with increased p53 detection in the B16 murine melanoma. DNA Cell Biol 13: 343-351, 1994.
8. 7a Chen HL, Fernig DG, Rudland PS, Sparks A, Wilkinson MC and Barraclough R: Binding to intracellular targets of the metastasis-inducing protein, S100A4 (p9Ka). Biochem Biophys Res Commun 286: 1212-1217, 2001.
9. Grigorian M and Lukanidin E: Metastasis-inducing Mts1/S100A4 protein binds to tumour suppressor p53 protein. Russ J Genet 39: 748-755, 2003.
10. Schmidt-Hansen B, Klingelhofer J, Grum-Schwensen B, Christensen A, Andresen S, Kruse C, Hansen T, Ambartsumian N, Lukanidin E and Grigorian M: Functional significance of metastasis-inducing S100A4(Mts1) in tumour-stroma interplay. J Biol Chem 279: 24498-24504, 2004.
11. Greenway S, van Suylen RJ, Sarvaas GD, Kwan E, Ambartsumian N, Lukanidin E and Rabinovitch M: S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. Am J Pathol 164: 253-262, 2004.
12. El Naaman C, Grum-Schwensen B, Mansouri A, Grigorian M, Santoni-Rugiu E, Hansen T, Kriajevska M, Schafer BW, Heizmann CW, Lukanidin E and Ambartsumian N: Cancer predisposition in mice deficient for the metastasis-associated Mts1 (S100A4) gene. Oncogene 23: 3670-3680, 2004.
13. Fernandez-Fernandez MR, Veprintsev DB and Fersht AR: Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor. Proc Natl Acad Sci USA 102: 4735-4740, 2005.
14. Cajone F and Sherbet GV: Stathmin is involved in S100A4-mediated regulation of cell cycle progression. Clin Exptl Metastasis 17: 865-871, 1999.
15. Daoud SS, Munson PJ, Reinhold W, Young L, Prabhu VV, Yu QA, LaRose J, Kohn KW, Weinstein JN and Pommier Y: Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: A pharmacogenomic study. Cancer Res 63: 2782-2793, 2003.
16. Yeh JRJ, Mohan R and Crews CM: The anti-angiogenic agent TNP-470 requires p53 and p21(CIP/WAF) for endothelial cell growth arrest. Proc Natl Acad Sci USA 97: 12782-12787, 2000.
17. Zhang Y, Griffith EC, Sage J, Jacks T and Liu JO: Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21(WAF1/CIP1). Proc Natl Acad Sci USA 97: 6427-6432, 2000.
18. Lien WH, Chen CK, Lai LY, Chen YH, Wu MP and Wu LW: Participation of cyclin D1 deregulation in TNP-470-mediated cytostatic effect: involvement of senescence. Biochem Pharmacol 68: 729-738, 2004.
19. Sherbet GV, Parker C, Usmani BA and Lakshmi MS: Epidermal growth factor receptor status correlates with cell proliferation-related 18A2/mts1 gene expression in human carcinoma cell lines. Ann N Y Acad Sci 768: 272-276, 1995.
20. Albertazzi E, Cajone F, Leone BE, Naguib RNG, Lakshmi MS and Sherbet GV: The expression of metastasis associated genes mts1 and nm23 in carcinoma of the breast are related to disease progression. DNA Cell Biol 17: 335-342, 1998.
21. Boerner JL, Gibson MA, Fox EM, Posner ED, Parsons SJ, Silva CM and Shupnik MA: Estrogen negatively regulates epidermal growth factor (EGF)-mediated signal transducer and activator of transcription 5 signaling in human EGF family receptor-over expressing breast cancer cells. Mol Endocrinol 19: 2660-2670, 2005.
22. Stabile LP, Lyker JS, Gubish CT, Zhang WP, Grandis JR and Siegfried JM: Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 65: 1459-1470, 2005.
23. Grigorian M, Ambartsumian N, Lykkesfeldt AE, Bastholm L, Elling F, Georgiev G and Lukanidin E: Effect of mts1 (S100A4) expression on the progression of human breast cancer cells. Int J Cancer 67: 831-841, 1996.
24. Tarbe N, Losch S, Burtscher H, Jarsch M and Weidle UH: Identification of rat pancreatic carcinoma genes associated with lymphogenous metastasis. Anticancer Res 22: 2015-2027, 2002.
25. Farrow B, Sugiyama Y, Chen A, Uffort E, Nealon W and Evers M: Inflammatory mechanisms contributing to pancreatic cancer development. Annals Surg 239: 763-769, 2004.
26. Hernan R, Fasheh R Calabrese C, Frank AJ, Maclean KH, Allard D, Barraclough R and Gilbertson RJ: ERBB2 upregulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 63: 140-148, 2003.
27. Zhang H, Ma G, Dong M, Zhao MF, Shen XD, Ma ZG and Guo KJ: Epidermal growth factor promotes invasiveness of pancreatic cancer cells through NF-kappa B-mediated proteinase productions. Pancreas 32: 101-109, 2006.
28. Arora A and Scholar EM: Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exptl Therapeutics 315: 971-979, 2005.
29. McIntyre JA, Castaner J and Leeson PA: Canertinib dihydrochloride - oncolytic drug HER (ErbB) inhibitor. Drugs Future 30: 771-779, 2005.
30. Agrawal A, Gutteridge E, Gee JMW, Nicholson RI and Robertson JFR: Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocrine-related Cancer 12: S135-S144, 2005.
31. Wakeling AE: Inhibitors of growth factor signalling. Endocrine-related Cancer 12: S183-S187, 2005.
32. Vadgama J, Wu Y and Mehta M: HER-2/neu over-expression in breast cancer: Methods of detection and therapeutic implications. In: Molecular and Cellular Pathology of Cancer Progression and Prognosis, Sherbet GV (ed.). Research Signpost, Trivandrum, pp. 327-358, 2006.
33. Bianco AR: Targeting c-erbB2 and other receptors of the C-ErbB family: rationale and clinical applications. J Chemother 16: 52-54, 2004.
34. Agus DB, Gordon MS, Taylor C, Natale, RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM and Fyfe G: Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23: 2534-2543, 2005.
35. Davies MPA, Rudland PS, Robertson L, Parry EW, Jolicoeur P and Barraclough R: Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours. Oncogene 13: 1631-1637, 1996.
36. Li CL, Martinez V, He B, Lombet A and Perbal B: A role for CCN3 (NOV) in calcium signalling. J Clin Pathol Mol Pathol 55: 250-261, 2002.
37. 2+ and the calmodulin inhibitor W-7 alter the expression of the metastasis associated genes mts1 and nm23 in metastatic variants of the B16 murine melanoma. Melanoma Res 2: 337-343, 1992.
38. Lakshmi MS, Parker C and Sherbet GV: Metastasis associated mts1 and nm23 genes affect tubulin polymerisation in B16 melanomas: a possible mechanism of their regulation of metastatic behaviour of tumours. Anticancer Res 13: 299-304, 1993.
39. Sherbet GV and Cajone F: Stathmin in cell proliferation and cancer progression. Cancer Genomics Proteomics 2: 227-238, 2005.
40. Ford HL, Silver DL, Kachar B, Sellers JR and Zain SB: Effect of Mts1 on the structure and activity of no muscle myosin II. Biochemistry 36: 16321-16327, 1997.
41. 39a Ford HL and Zain SB: Interaction of metastasis-associated mts1 protein with no muscle myosin. Oncogene 10: 1597-1605, 1995.
42. Kriajevska M, Bronstein IB, Scott DJ, Tarabykina S, Fischer-Larsen M, Issinger O and Lukanidin E: Metastasis-associated protein Mts1 (S100A4) inhibits CK2-mediated phosphorylation and self-assembly of the heavy chain of no muscle myosin. Biochim Biophys Acta 1498: 252-263, 2000.
43. Belot N, Pochet R, Heizmann CW, Kiss R and Decaestecker C: Extracellular S100A4 stimulates the migration rate of astrocytic tumor cells by modifying the organization of their actin cytoskeleton. Biochim Biophys Acta Proteins Proteomics 1600: 74-83, 2002.
44. Perbal B, Brigstock DR and Lau LF: Report on the second international workshop on the CCN family of genes. Mol Pathol 56: 80-85, 2003.
45. Goppelt-Struebe M, Hahn A, Iwanciw D, Rehm M and Banas B: Regulation of connective tissue growth factor (ccn2; ctgf) gene expression in human mesangial cells: modulation by HMG CoA reductase inhibitors (statins). J Clin Pathol Mol Pathol 54: 176-179, 2002.
46. Satchi-Fainaro R, Mamluk R, Wang L, Short SM, Nagy JA, Feng D, Dvorak AM, Dvorak HF, Puder M, Mukhopadhyay, D and Folkman J: Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 7: 251-261, 2005.
47. Fritz G: HMG-CoA reductase inhibitors (statins) as anticancer drugs (Review). Int J Oncol 27: 1401-1409, 2005
48. Keirsebilck A, Bonne S, Bruyneel E, Vermassen P, Lukanidin E, Mareel M and van Roy F: E-cadherin and metastasin (mts-1/S100A4) expression levels are inversely regulated in two tumor cell families. Cancer Res 58: 4587-4591, 1998.
49. Moriyama-Kita M, Endo Y, Yonemura Y, Heizmann CW, Miyamori H, Sato H, Yamamoto E and Sasaki T: S100A4 regulates E-cadherin expression in oral squamous cell carcinoma. Cancer Lett 230: 211-218, 2005.
50. Yonemura Y, Endou Y, Kimura K, Fushida S, Bandou E, Taniguchi K, Kinoshita K, Ninomiya I, Sugiyama K, Heizmann CW, Schafer BW and Sasaki T: Inverse expression of S100A4 and E-cadherin is associated with metastatic potential in gastric cancer. Clin Cancer Res 6: 4234-4242, 2000.
51. Ikoma N, Yamazaki H, Abe Y, Oida Y, Ohnishi Y, Suemizu H, Matsumoto H, Matsuyama T, Ohta Y, Ozawa A, Ueyama Y and Nakamura M: S100A4 expression with reduced E-cadherin expression predicts distant metastasis of human malignant melanoma cell lines in the NOD/SCID/gamma(null)(C) (NOG) mouse model. Oncol Rep 14: 633-637, 2005.
52. Andersen K, Nesland JM, Holm R, Florenes VA, Fodstad O and Maelandsmo GM: Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Modern Pathol 17: 990-997, 2004.
53. Merzak A, Parker C, Koochekpour S, Sherbet GV and Pilkington GJ: Over expression of the 18A2/mts1 gene and down-regulation of the TIMP-2 gene in invasive human glioma cell lines in vitro. Neuropathol Appl Neurobiol 20: 614-619, 1994.
54. Bjornland K, Winberg JO, Odegaard OT, Hovig E, Loennechen T, Aasen AO, Fodstad O and Maelandsmo GM: S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. Cancer Res 59: 4702-4708, 1999.
55. Bellum SC and Carla Mouta C: Angiogenesis and lymphangiogenesis: the role of phosphoinositide 3-kinases in the signalling cascade. In: The Molecular and Cellular Pathology of Cancer Progression and Prognosis, Sherbet GV (ed.). Research Signpost, Trivandrum, pp. 53-72, 2006.
56. Ambartsumian N, Klingelhofer J, Grigorian M, Christensen C, Kriajevska M, Tulchinsky E, Georgiev G, Berezin V, Bock E, Rygaard J, Cao RH, Cao YH and Lukanidin E: The metastasis-associated Mts1 (S100A4) protein could act as an angiogenic factor. Oncogene 20: 4685-4695, 2001.
57. Rudland SDS, Martin L, Roshanlall C, Winstanley J, Leinster S, Platt-Higgins A, Carroll J, West C Barraclough, R and Rudland P: Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer. Clin Cancer Res 12: 1192-1200, 2006.
58. Sato Y: Aminopeptidases and angiogenesis. Endothelium 10: 287-290, 2003.
59. Endo H, Takenaga K, Kanno T, Satoh H and Mori S: Methionine aminopeptidase 2 is a new target for the metastasis-associated protein, S100A4. J Biol Chem 277: 26396-26402, 2003.
60. Bradshaw RA: Methionine aminopeptidase 2 inhibition: anti-angiogenesis and tumour therapy. Expert Opin Ther Patents 14: 1-6, 2004.
61. Asami Y, Kakeya H, Onose R, Chang YH, Toi M and Osada H: RK-805, an endothelial-cell-growth inhibitor produced by Neosartorya sp., and a docking model with methionine aminopeptidase-2. Tetrahedron 60: 7085-709, 2004.
62. Wang JY, Sheppard GS, Lou PP, Kawai M, BaMaung N, Erickson SA, Tucker-Garcia L et al: Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res 63: 7861-7869, 2003.
63. Kallander LS, Lu Q, Chen WF, Tomaszek T, Yang G and Tew D: 4-Aryl-1,2,3-triazole: a novel template for a reversible methionine aminopeptidase 2 inhibitor, optimized to inhibit angiogenesis in vivo. J Medicinal Chem 48: 5644-5647, 2005.
64. Chun E, Han CK, Yoon JH, Sim TB, Kim YK and Lee KY: Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model. Int J Cancer 114: 124-130, 2005.
65. Hori A, Imaeda Y, Kubo K and Kusaka M: Novel benzimidazole derivatives selectively inhibit endothelial cell growth and suppress angiogenesis in vitro and in vivo. Cancer Lett 183: 53-60, 2002.
66. Yoshida T, Kaneko Y, Tsukamoto A, Han K, Ichinose M and Kimura S: Suppression of hepatoma growth and angiogenesis by a fumagillin derivative TNP470: possible involvement of nitric oxide synthase. Cancer Res 58: 3751-3756, 1998.
67. Burchill SA and Roberts P: Molecular and genetic abnormalities in tumours of the Ewing's sarcoma family (ESFT). In: The Molecular and Cellular Pathology of Cancer Progression and Prognosis, Sherbet GV (ed.). Research Signpost, Trivandrum, pp. 221-234, 2006.
68. Katayama S, Nakayama T, Ito M, Naito S and Sekine I: Expression of the ets-1 proto-oncogene in human breast carcinoma: differential expression with histological grading and growth pattern. Histol Histopath 20: 119-126, 2005.
69. Buggy Y, Maguire TM, McGreal G, McDermott E, Hill ADK, O'Higgins N and Duffy MJ: Over expression of the Ets-1 transcription factor in human breast cancer. Br J Cancer 91: 1308-1315, 2004.
70. Span PN, Manders P, Heuvel JJ, Thomas CMG, Bosch RR, Beex LV and Sweep CGJ: Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene 21: 85-6-8509, 2002.
71. Alipov G, Nakayama T, Ito M, Kawai K, Naito S, Nakashima M, Niino D and Sekine I: Over expression of Ets-1 proto-oncogene in latent and clinical prostatic carcinomas. Histopathology 46: 202-208, 2005.
72. Fujimoto J, Aoki I, Toyoki H, Khatun S, Sato E, Sakaguchi H and Tamaya T: Clinical implications of expression of ETS-1 related to angiogenesis in metastatic lesions of ovarian cancers. Oncology 66: 420-428, 2004.
73. Fujimoto J, Aoki I, Toyoki H, Khatun S and Tamaya T: Clinical implications of expression of ETS-1 related to angiogenesis in uterine cervical cancers. Ann Oncol 13: 1598-1604, 2002.
74. Tokuhara K, Ogata Y, Nakagawa M and Shirouzu K: Ets-1 expression in vascular endothelial cells as an angiogenic and prognostic factor in colorectal carcinoma. Int Surg 88: 25-33, 2003.
75. Hegen A, Koidl S, Weindel K, Marme D, Augustin HG and Fiedler U: Expression of angiopoietin-2 in endothelial cells is controlled by positive and negative regulatory promoter elements. Arterioscler Thromb Vase Biol 24: 1803-1809, 2004.
76. Hasegawa Y, Abe M, Yamazaki T, Niizeki O, Shiiba K, Sasaki I and Sato Y: Transcriptional regulation of human angiopoietin-2 by transcription factor Ets-1. Biochem Biophys Res Commun 316: 52-58, 2004.
77. Hashiya N, Jo N, Aoki M, Matsumoto K, Nakamura T, Sato Y, Ogata N, Ogihara T, Kaneda Y and Morishita R: In vivo evidence of angiogenesis induced by transcription factor ets-1 - Ets-1 is located upstream of angiogenesis cascade. Circulation 109: 3035-3041, 2004.
78. Fuchs B, Inwards CY and Janknecht R: Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin Cancer Res 10: 1344-1353, 2004.
79. Adam M, Schmidt D, Wardelmann E, Wernert N and Albers, P: Angiogenetic proto-oncogene ets-1 induced neovascularization is involved in the metastatic process of testicular germ cell tumors. Eur Urol 44: 329-336, 2003.
80. Mukherjee T, Kumar A, Mathur M, Chattopadhyay TK and Ralhan R: Ets-1 and VEGF expression correlates with tumor angiogenesis, lymph node metastasis, and patient survival in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 129: 430-436, 2003.
81. Hahne JC, Okuducu AF, Kaminski A, Florin A, Soncin F and Wernert N: Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth. Oncogene 24: 5384-5388, 2005.
82. Tsutsumi S, Kuwano H, Nagashima N, Shimura T, Mochiki E and Asao T: Ets-1 expression in gastric cancer. HepatoGastroenterol 52: 654-656, 2005.
83. Takigawa M, Nishida Y, Suzuki F, Kishi J, Yamashita K and Hayakawa T: Induction of angiogenesis in chick yolk sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP AND TIMP-2). Biochem Biophys Res Commun 171: 1264-1271, 1990.
84. Johnson MD, Kim HRC, Chesler L, Tsaowu G, Boucki N and Polverini PJ: Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 160: 194-202, 1994.
85. Kanda K, Ueda M, Futakuchi H, Yamaguchi H, Mori K, Terai Y and Ueki M: Transcriptional expression of the genes implicated in angiogenesis and tumor invasion in cervical carcinomas. Gynaecol Oncol 98: 453-461, 2005.
86. Onisto M, Slongo ML, Gregnanin L, Gastaldi T, Carli M and Rosolen A: Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines. Int J Oncol 27: 791-798, 2005.
87. Behrens P, Mathiak M, Mangold E, Kirdorf S, Wellmann A, Fogt F, Rothe M, Florin A and Wernert N: Stromal expression of invasion-promoting, matrix-degrading proteases MMP-1 and -9 and the ets 1 transcription factor in hnpcc carcinomas and sporadic colorectal cancers. Int J Cancer 107: 183-188, 2003.
88. Tomita N, Morishita R, Taniyama Y, Koike H, Aoki M, Shimizu H, Matsumoto K, Nakamura T, Kaneda Y and Ogihara T: Angiogenic property of hepatocyte growth factor is dependent on pregulation of essential transcription factor for angiogenesis ets-1. Circulation 707: 1411-1417, 2003.
89. Wemert N, Okuducu AF and Pepper MS: Ets 1 is expressed in capillary blood vessels but not in lymphatics. J Pathol 200: 561-567, 2003.
90. Shimizu S, Kageyama M, Yasuda M, Sasaki D, Naito S, Yamamoto T and Kiuchi Y: Stimulation of in vitro angiogenesis by nitric oxide through the induction of transcription factor ETS-1. Int J Biochem Cell Biol 36: 114-122, 2004.
91. Nosho K, Yoshida M, Yamamoto H, Taniguchi H, Adachi Y, Mikami M, Hinoda Y and Imai K: Association of Ets-related transcriptional factor E1AF expression with over expression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis. Carcinogenesis 26: 892-899, 2005.
92. Kwapiszewska G, Wilhelm J, Wolff S, Laumanns I, Koenig IR, Ziegler, A, Seeger W, Bohle RM, Weissmann N and Fink L: Expression profiling of laser microdissected intrapulmonary arteries in hypoxia-induced pulmonary hypertension. Respiratory Res 6: article 109, 2005.
93. Fujimoto J, Toyoki H, Jahan I, Alam SM, Sakaguchi H, Sato E and Tamaya T: Sex steroid-dependent angiogenesis in uterine endometrial cancers. J Steroid Biochem Mol Biol 93: 161-165, 2005.
94. Keezer SM, Ivie SE, Krutzsch HC, Tandle A, Libutti SK and Roberts DD: Angiogenesis inhibitors target the endothelial cell cytoskeleton through altered regulation of heat shock protein 27 and cofilin. Cancer Res 63: 6405-6412, 2003.
95. Sumi T, Matsumoto K and Nakamura T: Mitosis-dependent phosphorylation and activation of LIM-kinase. Biochem Biophys Res Commun 290: 1315-1320, 2002.
96. Gunnersen JM, Spirkoska V, Smith PE, Danks RA and Tan SS: Growth and migration markers of rat C6 glioma cells identified by serial analysis of gene expression. Glia 32: 146-154, 2000.
97. Ding SJ, Shao XX, Zheng R, Tang ZY and Xia QC: Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC07-L, with different metastasis potentials. Proteomics 4: 982-994, 2004.
98. Zippo A, De Robertis A, Bardelli M, Galvagni F and Oliviero S: Identification of Flk-1 target genes in vasculogenesis: Pim-1 is required for endothelial and mural cell differentiation in vitro. Blood 103: 4536-4544, 2004.
99. Ohta Y, Nozawa H, Tanaka Y, Oda M and Watanabe Y: Increased vascular endothelial growth factor and vascular endothelial growth factor-C and decreased NM23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. J Thoracic Cardiovasc Surg 119: 804-813, 2000.
100. Duenas-Gonzalez A, Isales CM, Abad-Hernandez, MDM, Gonzalez-Sarmiento R, Sangueza O and Rodriguez-Commes J: Expression of inducible nitric oxide synthase in breast cancer correlates with metastatic disease. Modern Pathol 10: 645-649, 1997.
101. Albig AR and Schiemann WP: Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells. DNA Cell Biol 23: 367-379, 2004.
102. Spurgeon KR, Donohoe DL and Basile DP: Transforming growth factor-beta in acute renal failure: receptor expression, effects on proliferation, cellularity, and vascularization after recovery from injury. Am J Physiol-Renal Physiol 288: F568-F577, 2005.
103. Greene LM, Twal WO, Duffy MJ, McDermott EW, Hill AD, O'Higgins NJ, McCann A, Dervan P, Argraves W and Gallagher WM: Elevated expression and altered processing of fibulin-1 protein in human breast cancer. Br J Cancer 88: 871-878, 2003.
104. Merklinger SL, Wagner RA, Spiekerkoetter E, Hinek A, Knutsen RH, Kabir MG, Desai K, Hacker S, Wang LL, Cann GM, Ambartsumian NS, Lukanidin E, Bernstein D, Husain M, Mecham RP, Starcher B, Yanagisawa H and Rabinovitch M. Increased fibulin-5 and elastin in S100A4/Mts1 mice with pulmonary hypertension. Circulation Res 97: 596-604, 2005.
105. Turner J and Crossley M: Cloning and characterization of mCtBP2, a co-repressor that associates with basic Kruppel-like factor and other mammalian transcriptional regulators. EMBO J 17: 5129-5140, 1998.
106. van Vliet, Turner J and Crossley M: Human Kruppel-like factor 8: a CACCC-box binding protein that associates with CtBP and represses transcription. Nucleic Acids Res 28: 1955-1962, 2000.
107. Herbert C, Nelson G, Barraclough R, Neoptolemos JP and Greenhalf W: Regulation of expression from the S100A4 promoter by BKLF and CtBP-2. Pancreatology 2: 217-361, 2002.
108. Kato C, Kojima T, Komaki M, Mimori K, Duarte WR, Takenaga K and Ishikawa I: S100A4 inhibition by RNAi upregulates osteoblast related genes in periodontal ligament cells. Biochem Biophys Res Commun 326: 147-153, 2005.
109. Hovig E, Maelandsmo G, Mellingsaeter T, Fodstad O, Mielewczyk SS, Wolfe J and Goodchild J: Optimization of hammerhead ribozymes for the cleavage of S100A4 (CAPL) mRNA. Antisense Nucleic Acid Drug Develop 11: 67-75, 2001.
110. Takenaga K, Nakamura Y and Sakiyama S: Expression of antisense RNA to S100A4 gene encoding an S100-related calcium-binding protein suppresses metastatic potential of high-metastatic Lewis lung carcinoma cells. Oncogene 14: 331-337, 1997.
111. Gao XN, Tang SQ and Zhang XF: S100A4 antisense oligodeoxynucleotide suppresses invasive potential of neuroblastoma cells. J Paediat Surg 40: 648-652, 2005.
112. Andersen K, Smith-Sorensen B, Pedersen KB, Hovig E, Myklebost O, Fodstad O and Maelandsmo GM: Interferon-gamma suppresses S100A4 transcription independently of apoptosis or cell cycle arrest. Br J Cancer 88: 1995-2001, 2001.
113. Pedersen KB, Andersen K, Fodstad O and Maelandsmo GM: Sensitization of interferon-gamma induced apoptosis in human osteosarcoma cells by extracellular S100A4. BMC Cancer 4: 38-52, 2004.
114. Pedersen MV, Kohler LB, Grigorian M, Novitskaya V, Bock E, Lukanidin E and Berezin V: The Mts1/S100A4 protein is a neuroprotectant. J Neurosci Res 77: 777-786, 2004.
115. Rosty C, Ueki T, Argani P, Jansen M, Yeo CJ, Cameron JL, Hruban RH and Goggins M: Over expression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am J Pathol 760: 45-50, 2002.
116. Sato N, Maitra A, Fukushima N, van Heek NT, Matsubayashi H, Iacobuzio-Donahue CA, Rosty C and Goggins M: Frequent hypomethylation of multiple genes over expressed in pancreatic ductal adenocarcinoma. Cancer Res 63: 4158-4166, 2003.
117. Silverman LR: DNA methyltransferase inhibitors in myelodysplastic syndrome. Best Practice Res Clin Haematol 17: 585-594, 2004.
118. Wang GZ, Rudland PS, White MR and Barraclough R: Interaction in vivo and in vitro of the metastasis-inducing S100 protein, S100A4 (p9Ka) with S100A1. J Biol Chem 275: 11141-11146, 2000.
119. Tarabykina S, Kriajevska M, Scott DJ, Hill TJ, Lafitte D, Derrick PJ, Dodson GG, Lukanidin E and Bronstein I: Heterocomplex formation between metastasis-related protein S100A4 (Mts1) and S100A1 as revealed by the yeast two-hybrid system. FEBS Lett 475: 187-191, 2000.
120. Zhang S, WangGZ, Liu D, Bao ZZ, Fernig DG, Rudland PS and Barraclough R: The C-terminal region of S100A4 is important for its metastasis-inducing properties. Oncogene 24: 4401-4411, 2005.
121. Lakshmi MS and Sherbet GV: Expression of transmembrane glycoprotein CD44 and metastasis associated gene 18A2/mts1 gene in B16 murine melanoma. Anticancer Res 17: 3451-3456, 1997.
122. Semov A, Moreno MJ, Onichtchenko A, Abulrob A, Ball M, Ekiel I, Pietrzynski G, Stanimirovic D and Alakhov V: Metastasis-associated protein S100A4 induces angiogenesis through interaction with annexin II and accelerated plasmin formation. J Biol Chem 280: 20833-20841, 2005.